Scholarlink

<p>Vascular dementia (VaD) is a leading cause of cognitive impairment, typically occurring due to conditions that reduce blood flow to the brain. Increasing evidence indicates that neuroinflammation plays a key role in the progression of VaD, with Toll-like receptor 4 (TLR4) emerging as a key regulator of innate immune activation and inflammatory amplification. Therefore, therapeutic agents capable of targeting TLR4-driven neuroinflammation may represent a rational approach to mitigating disease progression in VaD. In this context, piracetam, a nootropic agent used for cognitive disorders, has shown potential in modulating several pathological mechanisms associated with VaD. Hence, this review aims to summarize recent insights into TLR4 signaling in VaD and to critically evaluate experimental and clinical evidence regarding the capacity of piracetam to influence these disease-relevant pathways. In particular, studies reporting the suppression of TLR4-mediated neuroinflammatory responses by piracetam are discussed, along with emerging evidence that piracetam may also modulate signaling cascades that converge on TLR4-associated inflammatory networks. Finally, the limitations of the current evidence are addressed, and further research directions are proposed to determine whether modulation of TLR4-centered inflammatory pathways by pleiotropic agents such as piracetam can provide clinically meaningful benefits in vascular cognitive impairment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neuroprotective effects of piracetam in vascular dementia: a review of toll-like receptor 4 -mediated neuroinflammatory pathways

  • 期刊论文

  • 发表日期：

    2026年5月15日

查看全文
  • Phakkawat Thangwong,
  • Chainarong Tocharus,
  • Jiraporn Tocharus

摘要

Vascular dementia (VaD) is a leading cause of cognitive impairment, typically occurring due to conditions that reduce blood flow to the brain. Increasing evidence indicates that neuroinflammation plays a key role in the progression of VaD, with Toll-like receptor 4 (TLR4) emerging as a key regulator of innate immune activation and inflammatory amplification. Therefore, therapeutic agents capable of targeting TLR4-driven neuroinflammation may represent a rational approach to mitigating disease progression in VaD. In this context, piracetam, a nootropic agent used for cognitive disorders, has shown potential in modulating several pathological mechanisms associated with VaD. Hence, this review aims to summarize recent insights into TLR4 signaling in VaD and to critically evaluate experimental and clinical evidence regarding the capacity of piracetam to influence these disease-relevant pathways. In particular, studies reporting the suppression of TLR4-mediated neuroinflammatory responses by piracetam are discussed, along with emerging evidence that piracetam may also modulate signaling cascades that converge on TLR4-associated inflammatory networks. Finally, the limitations of the current evidence are addressed, and further research directions are proposed to determine whether modulation of TLR4-centered inflammatory pathways by pleiotropic agents such as piracetam can provide clinically meaningful benefits in vascular cognitive impairment.